Skip to main content
uniQure N.V. logo

uniQure N.V. — Investor Relations & Filings

Ticker · QURE ISIN · NL0010696654 LEI · 724500RPCTZLFYJZ3S98 US Manufacturing
Open in API
Filings indexed 859 across all filing types
Latest filing 2016-09-22 Board/Management Inform…
Country NL Netherlands
Listing US QURE

About uniQure N.V.

https://www.uniqure.com/

uniQure N.V. is a gene therapy company focused on developing and commercializing treatments for patients with rare and severe diseases. The company utilizes its adeno-associated virus (AAV) based technology platform to create single-administration therapies with the potential for curative results. Its research and development pipeline is concentrated on liver-directed and central nervous system (CNS) disorders, with a key clinical program targeting Huntington's disease. uniQure aims to deliver transformative medicines by translating scientific innovation into viable treatments.

Recent filings

Filing Released Lang Actions
6-K
Board/Management Information Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, uniQure N.V., dated September 22, 2016. The text explicitly states that the filing includes a press release announcing changes to management and the board of directors. There is no indication of financial data, earnings, or other report types. The document is short (2232 characters) and primarily announces management and board changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG).
2016-09-22 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, uniQure N.V., with the SEC. It includes a press release about NASDAQ notifying the company that its Board of Directors did not meet independence requirements and a cure period was provided. The document is short (2497 characters) and primarily serves as a regulatory announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or detailed governance information but rather a notification of a regulatory compliance issue related to board composition. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-09-16 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, uniQure N.V., with the SEC. It includes a press release announcing unaudited consolidated financial results for the three and six months ended June 30, 2016, and also furnishes unaudited consolidated financial statements with related management's discussion and analysis for the same periods. The presence of unaudited financial statements and MD&A for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is 2614 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR).
2016-08-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, uniQure N.V., dated July 27, 2016. It includes a press release announcing updated clinical data from an ongoing Phase I/II trial. The document length is 2332 characters, which is relatively short and primarily serves as an announcement of clinical trial data rather than a detailed financial or management report. Form 6-K filings typically serve as current reports for foreign issuers to disclose material information. Given the content and format, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories such as financial reports or management information.
2016-07-27 English
6-K
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, uniQure N.V. It reports the establishment and execution of a Rule 10b5-1 trading plan by the CEO, detailing insider share purchases. The content focuses on a director's personal share transactions rather than company financial results, governance changes, or other report types. The document length is short (2818 characters) and contains specific insider trading information. Therefore, it fits the category of Director's Dealing (DIRS).
2016-06-30 English
6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, uniQure N.V., reporting the results of the 2016 Annual General Meeting (AGM) held on June 15, 2016. It details the voting outcomes on various agenda items including adoption of annual accounts, discharge of board members, appointment of directors, amendments to governance structure, remuneration policy, share option grants, and authorization for share repurchase. The content focuses on the official voting results from the shareholder meeting rather than the meeting materials or presentations. The document length is 9515 characters, which is sufficient to contain detailed voting results. Therefore, this filing corresponds to Declaration of Voting Results & Voting Rights Announcements (DVA).
2016-06-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.